Phase 2 Study to Evaluate the Efficacy of High Dose Ranibizumab as Adjuvant in the Treatment of Choroidal Melanoma
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
To evaluate the safety/efficacy of intravitreal injection of high dose Ranibizumab combined with TTT + ICG-based photodynamic therapy in the treatment of Choroidal Melanoma using the incidence and severity of adverse events.
We are going to evaluate if the patients develop adverse events such as: Branch retinal vein occlusions, decreased visual acuity or cystoid macular edema. It is important to determine the local control of the tumor.
Peter E Liggett, MD
New England Retina Associates
United States: Food and Drug Administration
|New England Retina Associates||Hamden, Connecticut 06518|